CYLD is a gene mutated in familial cylindromatosis and related diseases, leading to the development of skin appendages tumors. Although the deubiquitinase CYLD is a skin tumor suppressor, its role in skin physiology is unknown. Using skin organotypic cultures as experimental model to mimic human skin, we have found that CYLD acts as a regulator of epidermal differentiation in humans through the JNK signaling pathway. We have determined the requirement of CYLD for the maintenance of epidermal polarity, keratinocyte differentiation and apoptosis. We show that CYLD overexpression increases keratinocyte differentiation while CYLD loss of function impairs epidermal differentiation. In addition, we describe the important role of CYLD in the control of human non-melanoma skin cancer progression. Our results show the reversion of the malignancy of human squamous cell carcinomas that express increased levels of CYLD, while its functional inhibition enhances the aggressiveness of these tumors which progress toward spindle cell carcinomas. We have found that the mechanisms through which CYLD regulates skin cancer progression include the control of tumor differentiation, angiogenesis and cell survival. These findings of the role of CYLD in human skin cancer prognosis make our results relevant from a therapeutic point of view, and open new avenues for exploring novel cancer therapies.
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The epidermis is a stratified squamous epithelium composed mainly of keratinocytes. Basal keratinocytes proliferate and give rise to differentiated cells, which, upon full maturation, undergo enucleation and generate the squamous cornified layer. 1 Several molecules have been found to develop important roles in this differentiation process. Among them, the c-Jun-NH 2 -terminal kinase (JNK) signaling pathway has an emergent role, 2, 3 as the inhibition of JNK activity in keratinocyte induces epidermal differentiation (stratification and production of cornified envelopes), while augmented JNK activity delays or inhibits keratinocyte differentiation. 2 To be functional, keratinocytes must also maintain an apico-basal polarization, b-catenin being an important molecule to the generation of a polarized epithelial phenotype; 4, 5 that is, perturbed b-catenin location (cytoplasmic localization and reduced membranous expression) is associated to lack of differentiation, invasive potential and aggressive behaviour 6 in tumors. Disturbances of the balance proliferation/ differentiation/apoptosis of the epidermis result in epidermal disorders, such as hyperplasia, psoriasis and skin cancer. Non-melanoma skin cancers (NMSC): basal cell carcinomas (BCC) and squamous cell carcinomas (SCC) are the most common human malignancies.
CYLD is a tumor suppressor gene that was originally identified as a gene mutated in familial cylindromatosis, a genetic condition that predisposes patients for the development of skin appendages tumors. 7 CYLD deubiquitinating activity removes lysine-63 polyubiquitin chains. 7 Most of the mutations within the CYLD locus are located toward the carboxyl terminus of the protein, the position of the catalytic residues of ubiquitin hydrolase. 8, 9 Depending on the cellular context CYLD negatively regulates NF-kB and/or JNKsignaling pathways, resulting in suppression of cell proliferation. [10] [11] [12] [13] In keratinocytes, JNK activation promotes cell proliferation and inhibits differentiation, 2 whereas NF-kB appears uninvolved in epidermal differentiation. 14, 15 Besides its role in the familial cylindromatosis, additional studies have associated CYLD downregulation with the development of other types of human cancer including tumors of colon, lung and kidney, as well as melanomas and cervical and hepatocellular carcinomas. [16] [17] [18] [19] [20] Recently, we have demonstrated a relationship between the inhibition of CYLD function and an increase in aggressiveness of mouse NMSC. 21 However, although CYLD is ubiquitously expressed and its function as tumor suppressor is being actively investigated, little is known about its role in the homeostasis of the different tissues; particularly in the skin.
In this study we have analyzed the role of CYLD in the homeostasis and carcinogenesis of human skin. We have used skin organotypic cultures (also named skin equivalents) as experimental model to mimic human skin in vitro. Similar to the epidermis, the epithelium of the skin organotypic culture stratifies and differentiates. This model has allowed us to increase the expression or to inhibit the function of CYLD in a human-like context. As a result, we have found that forced expression of wild-type CYLD (CYLD WT ) both in HaCaT keratinocytes and in the skin equivalents enhances keratinocyte differentiation, while the inhibition of CYLD function by expression of a catalytically inactive form of CYLD impairs epidermal differentiation. CYLD WT overexpression is also able to induce the differentiation of human A431 squamous carcinoma (SCC) cell line. Our results show that CYLD controls skin differentiation through the JNK signaling pathway. In addition, using an in vivo xenograft model of skin carcinogenesis, we describe the important role of CYLD in the control of human NMSC progression.
Results

Forced expression of CYLD
WT in human keratinocytes. The HaCaT cell line, a non-tumoral immortalized human epidermal cell line commonly used in epidermal biology studies, 22 was employed. HaCaT cells maintain full epidermal differentiation capacity: when cultured in the absence of serum, they form stratification domes and express the early differentiation marker keratin K10. 22 Moreover, they are able to grow in organotypic cultures. 23 HaCaT Figure 1b) . The analysis of the early differentiation marker keratin K10, not expressed in undifferentiated cells, shows that at day 6 of differentiation the H-CYLD WT cells showed very high levels of K10, while the H-control cells did not show these levels of K10 expression until day 13 of differentiation ( Figure 1c ). Abundant cell death was observed in the supernatants of both, differentiated and conventional H-CYLD WT monolayer cultures; the analysis of the pro-apoptoctic protein Bax showed that it was highly expressed in the H-CYLD WT cells compared with the low levels of expression found in the H-control cells (Figure 1d ). Moreover, after UV light stimulation (an inductor of apoptosis in keratinocytes), 24 Bax was highly induced in the H-CYLD WT cells (Figure 1d ). Therefore, our results indicate that H-CYLD WT cells are prone to differentiation in addition to presenting a high rate of apoptosis. The decreased JNK pathway activation in the H-CYLD WT cells appears as a plausible mechanism for CYLD induction of keratinocytes differentiation. JNK signaling is a relevant pathway for keratinocyte differentiation and it is negatively regulated by CYLD. 13 The analysis of JNK phosphorylation (activation) in H-CYLD WT The inhibition of CYLD function in keratinocytes enhances the activation of the JNK pathway. To further confirm the CYLD function as regulator of keratinocyte differentiation and the relevance of the JNK pathway activation as a mechanism through which it may exerts its function, we generated HaCaT cells expressing a catalytically deficient CYLD mutant (CYLD C/S ) that carries the 601 C/S point mutation in the cysteine box of the deubiquitinase. 10 The expression of this transgene results in a catalytically inactive protein that competes with the endogenous CYLD. 10, 12, 20, 21, 25 HaCaT cells were stably transfected with CYLD C/S cDNA under the control of the b-actin promoter or with the empty vector, and different pooled stable transfectants were collected (designated as H-CYLD C/S and H-control cells). Western blot analysis showed increased levels of CYLD in the H-CYLD C/S cells ( Figure 3a) . We proved the lack of deubiquitination function of CYLD in the H-CYLD C/S cells ( Figure 3b ). We then studied the JNK activation pathway in the H-CYLD C/S cells. Both H-control and H-CYLD C/S cells were UV-irradiated and JNK activation in response to irradiation was analyzed. We found that JNK was highly activated after UV stimulation in the H-CYLD C/S cells (Figure 1d) . Therefore, our results show that in human keratinocytes the activation of JNK pathway was increased by the functional inhibition of CYLD while, consistently, it was diminished by the overexpression of CYLD WT (Figure 1d ).
The diminished function of CYLD impairs the differentiation of keratinocytes in human HaCaT skin equivalents. H-CYLD C/S skin equivalents were established. By 10 days of air-phase growth, H-control organotypic cultures formed a well-arranged tissue structure (Figure 3c ) with a basal layer formed by cylindrical cells of large nuclei and 4-6 layers of suprabasal cells, being the most superficial flattened cells with small nuclei in parallel to the basal membrane (Figure 3c ). In contrast, 10-days H-CYLD C/S skinequivalents showed a higher number of cell layers than the H-control skin equivalents, presenting heterogeneity in size, shape and orientation of the nuclei, resembling a disorganized epidermis with loss of cell polarity (Figure 3d) . Cells invading the subjacent matrix were also frequently seen in the H-CYLD C/S skin equivalents (Figures 3e and j) . To ascertain the possible cause of the loss of cell polarity observed in the CYLD C/S keratinocytes, we analyzed the WT skin equivalents by histological observation (e and g) and by anticleaved caspase 3 staining (C3C) (f and h). Arrows in e and g: apoptotic nuclei expression of b-catenin, as this is a relevant protein for the generation of a polarized epithelial phenotype. 4, 5 We found a normal, membranous localization of b-catenin at the cell-cell contacts of almost all the cell layers in both H-control and H-CYLD WT skin equivalents ( Figure 3k) ; by contrast, H-CYLD C/S skin equivalents showed a disorganized b-catenin location, that even was absent in most of the suprabasal cells (Figure 3k ). Even more, we also found that in H-CYLD C/S monolayer cultures, b-catenin appeared forming dots or diffusely distributed in the cytoplasm of most of the cells (Figure 3l ), in sharp contrast with the membranous pattern of b-catenin staining at the cell-cell contacts found in both H-control and H-CYLD WT cells. To analyze the differentiation of both the H-CYLD C/S and H-control skin-equivalents, we studied the expression of involucrin, a marker of early differentiation. We found an extensive staining in the suprabasal layers of H-control organotypic cultures (Figure 3f) . However, H-CYLD C/S skin equivalents only showed a very scarce involucrin staining, indicating their lack of differentiation (Figure 3g ). (Figures 3i and j) , compared with H-control skin equivalents (Figure 3h ), suggesting that CYLD C/S confers protection against cell death by apoptosis in human keratinocytes. Remarkably, these features found in H-CYLD C/S skin equivalents, that is, loss of cell polarity, altered b-catenin distribution, lack of differentiation, presence of invasion foci and cell resistance to apoptosis, are alterations that could evolve to epithelial dysplasia and premalignant changes.
Generation of human A431 squamous carcinoma cells expressing increased levels of CYLD WT or the catalytically inactive CYLD C/S mutant. To investigate the role of CYLD in the progression of human skin cancer, we generated A431 cells expressing the b-actin-CYLD WT and b-actin-CYLD C/S constructs (Figure 4a ; Supplementary Information SI-1a). They were designated as A-CYLD WT , A-CYLD C/S and A-control cells. We checked that the 
JNK activity is enhanced in A-CYLD C/S cells and inhibited in A-CYLD
WT cells. We analyzed the JNK pathway and found that in the non-stimulated state, the A-CYLD C/S cells presented an enhanced JNK activity (Figure 4d ). In addition, A-CYLD C/S cells also showed increased levels of P-JNK upon TNF-a stimulation. On the contrary, CYLD WT overexpression leads to a diminished JNK activation both in non-stimulated and in TNF-a-stimulated A-CYLD WT cells (Figure 4d ). The fact that the overexpression of CYLD in A431 cells and its functional inactivation lead to opposite effects in JNK activation, reinforces the relevance of this signaling pathway as mediator of CYLD functions in the A431 cells and is in agreement with the results found in the HaCaT keratinocytes.
Increased CYLD
WT expression in human squamous carcinoma cells improves the malignant phenotype of the SCCs while CYLD C/S enhances their aggressiveness. We performed xenograft carcinogenesis assays of the A431 cells. A-control, A-CYLD WT and A-CYLD C/S cells were injected into nude mice. The latency of macroscopic tumor appearance was similar, approximately 1 week, in the three cases (data not shown). Histologically, A-control tumors were solid SCCs and poorly differentiated (Figures 5a-c) . By contrast, tumors originated from A-CYLD WT were of better prognosis as in addition to poorly differentiated areas, they exhibit extensive regions of necrosis in the core of the tumor (Figures 5d-f) ; moreover, we also found A-CYLD WT tumors consisting of benign cysts (Figures 5g-i) . These features are compatible with the regression of the tumor. On the other hand, A-CYLD C/S tumors showed worse prognosis than A-control tumors, as they were anaplastic SCCs with high grade of cellular atypia and fusocellular morphology, resembling sarcomas or spindle-cell carcinomas (Figures 5j-k) .
The immunohistochemical analysis showed increased expression of CYLD in both A-CYLD WT and A-CYLD C/S tumors compared with the expression in A-control SCCs ( Figure 6 ). Low levels of expression of keratins K10 and K1 -reliable markers of well-differentiated tumors-were noted in A-control and A-CYLD WT SCCs, and they were not detected in A-CYLD C/S carcinomas ( Figure 6 and data not shown). Keratin K8, a marker of malignancy in skin tumors 26 showed extensive staining in both A-control and A-CYLD C/S carcinomas, while it was scarcely expressed in A-CYLD WT tumors ( Figure 6 ). K5 is a keratin typical of stratified epithelial tissues, expressed by normal skin and skin tumors that are lost in the later stages of tumor progression, that is, in spindle cell carcinomas. In agreement to their spindle-like phenotype, A-CYLD C/S tumors exhibited areas lacking K5 expression ( Figure 6 ). CD31 staining analysis of tumor blood vessels showed a network of large and lacunar vessels in A-CYLD C/S tumors while those found in A-CYLD WT were predominantly small and narrow; blood vessels developed in A-control carcinomas had an intermediate lumen diameter (Figures 7a-c) . The analysis of a-smooth muscle actin (SMA), a marker of smooth muscle cells and pericytes, showed a discontinuous expression in the A-CYLD C/S tumors indicating the immature and leaky nature of the blood vessels (Figure 7f ). By contrast, the vessels of the A-CYLD WT tumors were strongly stained demonstrating a mature and impermeable vascular phenotype (Figure 7d) . A-control tumors presented weak SMA staining although predominantly in a continuous way (Figure 7e) . Therefore, the vasculature analysis indicates an increased angionesis in A-CYLD C/S SCCs and consequently, poor prognosis. Finally we also check that A-CYLD WT tumors were prone to undergo apoptosis (SI-2). 
Discussion
Here we describe that CYLD acts as regulator of epidermal differentiation in humans. Our data demonstrate that alterations in CYLD expression in keratinocytes disrupt normal epidermal homeostasis: the forced expression of CYLD WT in human HaCaT keratinocytes and the skin equivalents enhance keratinocyte differentiation. By contrast, the expression of a mutant CYLD C/S that inhibits the endogenous CYLDdeubiquitination function impairs keratinocyte differentiation. We have found that JNK signaling pathway could be mediating the effects of CYLD in epidermal differentiation. In fact, it was previously reported that the inhibition of JNK activation in keratinocyte cultures in vitro induces almost all aspects of epidermal differentiation in vivo, including stratification and even production of cornified envelopes.
2 By contrast, augmented JNK activity delays or inhibits keratinocyte differentiation. 2 In line with these results, we have found diminished JNK activation in keratinocytes expressing CYLD WT , concomitant with an enhanced epidermal differentiation of the CYLD WT skin equivalents; additionally, we have found increased JNK activation in the CYLD C/S keratinocytes associated to an impaired epidermal differentiation of the CYLD C/S skin equivalents. This finding is relevant for our understanding of both the normal epidermal differentiation and its perturbations during pathological conditions. Importantly, we have discovered that CYLD WT also promotes the differentiation of A431 tumoral keratinocytes through inhibition of JNK activation. It may be significant clinically, because attenuating JNK activity could become a differentiation therapy-based approach for skin cancer in general and for tumors developed by familial cylindromatosis patients in particular.
Another finding of this study is the increased rate of apoptosis induced by CYLD WT both in tumoral and nontumoral human keratinocytes. This effect could be the consequence of the lack of JNK-mediated cell survival signaling due to the diminished JNK activation in these cells. 27 Our present results showing increased apoptosis in cells, and importantly, in skin tumors overexpressing CYLD WT , constitute an important finding for the identification of the mechanisms through which CYLD exerts its role as a tumor suppressor.
In addition to the impairment of keratinocyte differentiation, we have found that CYLD C/S expression provokes other alterations in skin equivalents such as the loss of cell polarity, likely due to the loss of b-catenin membranous distribution and its cytoplasmic accumulation. Maintenance of cell polarity is an essential requirement for the functionality and homeostasis of epithelial tissues, being b-catenin a key molecule in the maintenance of epithelial architecture as it regulates the polarity of cells and tissues. 28 Other features of the H-CYLD C/S skin equivalents are the formation of foci of basal invasion and resistance to apoptosis. Altogether, these changes could lead to epithelial dysplasia and reflect premalignant modifications, such as loss of epithelial differentiation and cell polarity, and the acquisition of invasive properties are frequently observed in malignant transformation. According to these pathological alterations found in H-CYLD C/S skin equivalents, CYLD C/S expression in A431 squamous carcinoma cells Several mechanisms have been proposed through which loss of CYLD may exert a role in tumor promotion. One of them is the hyperactivation of antiapoptotic signals in absence of functional CYLD in tumoral cells; 29 previously we described that CYLD C/S induced resistance to apoptosis in mouse skin tumors; 21 here we also extend this property to human skin cancer. We have also showed that CYLD C/S expression enhances angiogenesis in mouse skin carcinomas, 21 what constitutes a prominent feature of skin tumor progression. 30 Here we have also confirmed that in human SCCs CYLD C/S expression leads to a strong angiogenesis, increasing the size and permeability of blood vessels. Importantly, we have found as well that CYLD WT overexpression in SCCs reduces the diameter of the blood vessels and augments its maturity, which possibly make them unable to supply the nutrients needed for tumor progression.
Therefore our study is relevant because it established the role that CYLD has in normal skin physiology. The use of our skin equivalent model has allowed us to determine the importance of CYLD for the maintenance of epidermal polarity, keratinocyte differentiation and apoptosis. In addition, our results show the reversion of the malignancy of the SCCs that express increased levels of CYLD WT . The increase in apoptotic cell death of the A-CYLD WT tumors, together with the reduced angiogenesis could be responsible of the A-CYLD WT tumor regression observed in the carcinogenesis assays. Accordingly, SCCs defective in CYLD function are very aggressive as revealed by their progression toward spindle cell carcinomas, resistance to apoptosis and increased angiogenesis. These findings of the in vivo influence of CYLD in cancer prognosis make our results relevant from a therapeutic point of view, and open new avenues for exploring novel cancer therapies.
Materials and Methods DNA constructs. CYLD C/S cDNA was kindly provided by Dr. R Bernards and subcloned under the control of b-actin promoter. 21 b-actin-control construct has been described. 21 Cells and culture conditions. HaCaT and A431 cells were cultured in DMEM and 10% FCS. Cells were permanently transfected using the calcium phosphate method. In all transfections, the corresponding empty vectors were used as controls. Resistant colonies were selected using G418 and pooled (each pool was formed from approximately 20 different colonies). To allow HaCaT in vitro differentiation, cells were seeded and after reaching 60-80% confluence were grown in culture medium without FCS for different days. 22 Experiments were performed with 2-3 different pools of transfected cells of each genotype.
TNF-a and UV stimulation. When required, cells were treated with human TNFa (50 ng/ml; Sigma, Saint-Louis, Missouri, USA) or irradiated with UVB for the indicated times. For UVB irradiation, a Waldmann lamp (UV236B, TECNOSA, Nuevas Tecnologías SA, Barcelona, Spain)) was used. The light emitted was within the UVB range (280-320 nm), with a peak emission at 312 nm. HaCaT cells in PBS were irradiated with 800 mJ/cm 2 dose of UVB for 2 min. After irradiation, the cells were put in pre-warmed medium (371C) and collected 3 hs after irradiation.
Immunoblots. Antibodies used were: Actin, Bax, P-JNK, CYLD, tubulin (Sigma); ubiquitin (Cell Signaling Technology, Danvers, MA, USA); IKKg/NEMO (IMGENEX, San Diego, CA, USA). For immunoprecipitation, total lysates were obtained from untreated or TNFa-treated (50 ng/ml; Sigma) HaCaT and A431 cells. A total of 300 mg of lysate were immunoprecipated with and the anti-IKKg antibody and resolved on an SDS gel; probed with an antiubiquitin antibody, then stripped and reprobed with an antibody against IKKg (to show the amounts of IKKg immunoprecipitated).
Skin equivalents preparation. Human dermal fibroblasts were obtained according to Meana et al. 31 To generate skin equivalents, 1.5 ml of fibrinogen solution (from cryoprecipitated pig blood) was added to 5 ml of keratinocyte growth medium containing 2.5 Â 10 5 dermal fibroblasts. Immediately after that, 0.5 ml of 0.025 mM Cl 2 Ca, with 5.5 IU of bovine thrombin (Sigma-Aldrich Co., St. Louis, MO, USA) was added. The mixture was then placed on polycarbonate inserts (4 mM porous) in a six-well culture plate (Corning Costar Corp., Cambridge, MA, USA) and allowed to solidify at 37 1C for 2 h; 10 6 HaCaT cells were seeded on the fibrin matrix and grown to confluence. After 48 h of seeding, organotypic cultures were raised to the air-liquid interface for 6-12 days to achieve epidermal stratification.
Northern blotting. Total RNA was isolated by Trizol extraction (Gibco-BRL, San Francisco, CA, USA) following the manufacturer's instructions; 10 mg/lane RNA were probed for the expression of keratin K10. 22 A ribosomal 7S RNA probe was used as a loading control.
Xenograft model of carcinogenesis. Tumors were induced in nude mice (Hsd-Athymic Nude, Harlan Europe, Barcelona, Spain) by subcutaneous flank inoculation of 10 6 A431 control, CYLD WT or CYLD C/S cells. In all, 6-8 mice were inoculated in both flanks with each type of cells. Tumors were harvested 18 days post-cell injection. Experimental procedures were performed according to European and Spanish laws.
Histology and immunohistochemistry. Skin equivalents were fixed in formalin and embedded in paraffin. A431 tumors were fixed in methanol/acetone (1/1); in 70% ethanol or in formalin. Sections were stained with H&E for histopathological evaluation. Cells and tissue sections were stained with antibodies against keratins K1 (Covance, San Diego, CA, USA); K8, K10, involucrin and SMA (Sigma-Aldrich); b-catenin, CD31 (BD Biosciences, San Diego, CA, USA) and cleaved caspase 3 (Cell Signaling Technology).
Immunofluorescence. Cells were fixed in methanol/acetone (1/1). Alexa Fluor-594 goat antimouse IgG(H þ L) (Life Technologies SA, Paisley, UK) was used as fluorochrome.
Statistics. Statistical significance of data was assessed using the t-test and the Mann-Whitney (Wilcoxon) W test.
